Background
Over the last 15 years hand, foot and mouth disease (HFMD) has become an increasingly important cause of paediatric morbidity and mortality in Vietnam, and has placed a huge burden on healthcare services across the Asia-Pacific region [
1]. During outbreaks thousands of young children can be affected, and while HFMD is typically mild and self-limited, severe complications do occur, albeit rarely. Most notably, brainstem encephalitis may develop, presenting with autonomic nervous system (ANS) dysregulation around the third or fourth day of fever, sometimes with severe hypertension that may progress to cause cardiopulmonary failure [
2]. Typically, the period of ANS dysregulation lasts for 48-72 h, although in severe cases progression may be rapid, with death occurring within a few hours.
Management of ANS dysregulation in children presents particular challenges. A phosphodiesterase inhibitor, milrinone, has become the recommended therapy for severe HFMD, based on findings from two small studies, one retrospective, involving 65 participants overall, that reported benefit with milrinone in patients with cardiopulmonary failure [
3,
4]. For children with HFMD and ANS dysregulation, current Vietnamese Ministry of Health (MoH) guidelines recommend close observation without anti-hypertensive therapy when the systolic blood pressure (SBP) remains between the 95th percentile and 5 mmHg above the 99th percentile for age (i.e Stage 1 hypertension [
5]), but to intervene promptly (ideally within 1 h) with milrinone when the SBP exceeds the 99th centile for age plus 5 mmHg, (i.e. Stage 2 hypertension [
5]). However, despite use of high dose milrinone in accordance with these recommendations, some children continue to deteriorate, rapidly requiring ventilatory support and/or haemofiltration [
6]. Safety data regarding milrinone use in children are limited, although associations with tachyarrhythmias and acute renal failure have been documented [
7,
8].
Tetanus is another disease in which ANS dysregulation with severe hypertension occurs. Extrapolating from research in adults with tetanus [
9‐
11], and from experience in rare conditions such as phaeochromocytoma [
12,
13], magnesium sulfate (MgSO
4) has become the drug of choice to control ANS dysregulation in neonates with tetanus managed on the Paediatric Intensive Care Unit (PICU) at the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, using a regimen of 30–50 mg/kg per hour for up to 7 days titrated according to response [
14]. The physiological rationale underlying use of MgSO
4 in these circumstances relies on several properties of magnesium (Mg) ions: they compete with calcium (Ca) ions for receptors on vascular smooth muscle cells and can influence BP by modulating vascular tone [
15]; Mg has an important role in the classical pathway of nitric oxide (NO) release, with changes in extracellular Mg content modifying production and release of NO and thereby altering arterial tone [
16]; Mg also decreases the release of catecholamines after sympathetic stimulation [
17]. MgSO
4 is cheap, readily available and easily neutralised, and is therefore generally considered to be safe although little formal safety data is available for children [
18‐
20]. Given the experience with neonatal tetanus, when a major outbreak of HFMD commenced across the region in 2011 and use of high-dose milrinone proved inadequate to control ANS dysregulation in several cases, MgSO
4 was adopted at HTD as second line treatment with promising initial results [
21].
We hypothesized that intervention with MgSO
4 early, when hypertension due to ANS dysregulation first becomes apparent, might control cardiovascular instability more effectively and prevent progression to severe disease. In June 2014 we commenced a randomized, double-blind, placebo-controlled intervention trial to evaluate the efficacy and safety of MgSO
4 in 190 children with HFMD, ANS dysregulation and Stage 1 hypertension [
19]. However, over the next 2 years the number of HFMD cases seen across Vietnam declined dramatically, and by the end of 2016 the trial was stopped on the grounds of futility.
Over the 18-month period needed to obtain funding and the necessary ethical approvals to commence the trial, open-label MgSO4 was often used to treat severe cases. We therefore reviewed the hospital files of all non-trial severe HFMD cases managed on PICU from 2011 onwards to identify those who had received open-label MgSO4, aiming to gather additional data on the efficacy and safety of MgSO4 in severe HFMD, in the knowledge that major outbreaks of HFMD are likely to continue across the region in the coming years.
Discussion
Therapeutic options for severe HFMD remain limited [
1,
3,
4], despite the rapidly increasing burden of disease in the southeast Asian region over the last two decades, and the life-threatening nature of the clinical syndromes seen in a small proportion of cases [
33‐
37]. In this report we present the findings from two studies examining the efficacy and safety of intravenous MgSO
4 for management of ANS related hypertension in children with HFMD complicated by brainstem encephalitis.
Regrettably, the first study, a formal randomized double-blind placebo-controlled clinical trial, had to be stopped on the grounds of futility after enrolment of only 26 of the planned 190 cases when the regional epidemic of HFMD waned after 2014. Baseline information was similar between the two treatment arms, except that a greater proportion of children in the placebo group presented with more severe (Stage 2) hypertension. Conversely, EV-A71, the serotype generally associated with more severe outcomes [
38,
39], predominated in the MgSO
4 group. These differences between the treatment arms are likely to be random and related to the small number of participants recruited [
40], but there is the potential for an impact on the outcomes of interest.
With respect to efficacy, although we observed minor differences in the findings for a number of outcomes, generally favoring the MgSO
4 group, there were no significant differences in any of the primary and secondary outcomes evaluated in the trial. However, given the small number of patients enrolled and the low event rate, no conclusions can be drawn. The initial pilot data had suggested an effect in patients with Stage 2 hypertension who were already on milrinone [
21], and it is possible that among the less severe cases enrolled in the formal clinical trial, any potential beneficial effects were diluted.
More patients were included in the observational cohort analysis than in the clinical trial, but the final results also showed no statistically significant difference in the primary or secondary endpoints between those patients who did and did not receive MgSO
4. However, the differences we noted between the two groups – i.e. older age and a lower proportion of participants with EV-71 infection in the exposed than the control group – are both typically associated with less severe disease outcomes and may be confounders. In addition, the patients included in the observational cohort were generally more severe at baseline than those enrolled in the clinical trial (Stage 2 versus Stage 1 hypertension), and the Mg levels were generally lower than the levels achieved in the trial. In studies of MgSO
4 use in other conditions, the target therapeutic level has varied from 2 mmol/l to 5.5 mmol/l [
10,
19,
41]. For the trial we selected a target range of 1.8–2.5 mmol/l, with most patients achieving the upper end of this range early on. By contrast, more than half the patients in the observational cohort who received MgSO
4 did not achieve the 1.8 mmol/l lower margin, most likely because this was a new intervention in very sick children and clinicians were more cautious during the first year until they developed confidence that serious toxicity did not occur. Thus, it is possible that a therapeutic effect might have been demonstrated had we aimed for higher Mg levels.
Limited data are currently available regarding MgSO
4 safety profiles in children [
14,
19,
42], or the relationship between different therapeutic regimens and measured Mg and Ca levels. Our data are important in showing that potentially toxic Mg levels very rarely occurred using 30–50 mg/kg/hr. in sick children. Also, use of this regimen resulted in consistent plasma Mg levels with reciprocal plasma Ca responses in most study participants, indicating that detailed laboratory monitoring may not be necessary in the absence of clinical concerns suggesting toxicity. However, should more aggressive regimens be adopted in future studies, aiming to investigate efficacy at higher plasma Mg levels, regular monitoring of plasma levels would still be required.
Conclusions
To summarize, in these two studies we found no clear evidence of benefit but a dose of 30-50 mg/kg/hr. MgSO4 was safe in these children with severe HFMD. However, it is apparent that these data are not sufficient to address the hypothesis originally posed. The question of whether MgSO4 could be optimized as first line therapy remains an important one, and an adequately powered trial is still needed to properly evaluate its role in controlling hypertension in severe HFMD. Epidemiological observations over the last 20–30 years suggest that ongoing outbreaks of HFMD are likely to occur intermittently across the region in the coming years. To facilitate clinical research during epidemics of infectious disease advance preparation is crucial. The experience gained from these studies, both the general experience of setting up and conducting a complex trial on sick children during a major outbreak, and the more particular information regarding the positive safety profile of MgSO4 used in this way plus the information generated on dosing in relation to plasma Mg/Ca levels, should prove invaluable when the next epidemic occurs.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.